Anavex restores Nasdaq compliance after late 10-Qs
Anavex has cured its prior late 10-Q filings and received Nasdaq confirmation that its AVXL stock remains in full compliance with all listing standards.
Rhea-AI Filing Summary
ANAVEX LIFE SCIENCES CORP. (AVXL) reports that it has regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic reports with the SEC. Compliance was restored after the company filed its outstanding Form 10-Qs for the quarters ended March 31, 2026 and June 30, 2026.
Nasdaq has confirmed that Anavex now meets all Nasdaq listing standards, and the company’s common stock will continue to trade on the Nasdaq Global Select Market under the ticker AVXL.
Positive
- Nasdaq compliance restored: Anavex received confirmation that it has regained compliance with Nasdaq Listing Rule 5250(c)(1) and now meets all Nasdaq listing standards, eliminating the immediate risk of delisting tied to late periodic filings.
- Outstanding 10-Qs filed: The company filed its previously delayed Form 10-Qs for the quarters ended March 31, 2026 and June 30, 2026 on August 28, 2026, bringing its SEC periodic reporting up to date.
Negative
- Recent filing delinquency: Anavex previously received a Nasdaq delinquency notice on May 20, 2026 due to not timely filing its Form 10-Q for the quarter ended March 31, 2026, highlighting prior reporting and compliance lapses.
Insights
Analyzing...
8-K Event Classification
Key Figures
Key Terms
Nasdaq Listing Rule 5250(c)(1) regulatory
Nasdaq Global Select Market market
periodic filings regulatory
forward-looking statements regulatory
clinical-stage biopharmaceutical company medical
FAQ
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
| (State
or Other Jurisdiction of Incorporation) |
(Commission File Number) | (IRS
Employer Identification No.) | ||
| (Address of Principal Executive Offices) | (Zip Code) | |||
Registrant’s
Telephone Number, Including Area Code: 1-
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth
company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events.
As previously disclosed, on May 20, 2026, Anavex Life Sciences Corp. (“Anavex” or the “Company”) received a delinquency notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s inability to timely file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (“SEC”). On July 20, 2026, the Company timely submitted its plan to Nasdaq to regain compliance with Nasdaq Listing Rule 5250(c)(1). On August 28, 2026, the Company filed its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, and its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, with the SEC.
On September 2, 2026, the Company issued a press release (the “Press Release”) announcing that the Company has received confirmation from Nasdaq that the Company has regained compliance with Nasdaq Listing Rule 5250(c)(1).
A copy of the Press Release is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 | Press Release dated September 2, 2026. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ANAVEX LIFE SCIENCES CORP. | ||
| Date: September 2, 2026 | By: | /s/ Sandra Boenisch |
| Sandra Boenisch, CPA, CGA Principal Financial Officer, Treasurer | ||
EXHIBIT 99.1
Anavex Life Sciences Regains Compliance with Nasdaq Periodic Filing Requirement
Anavex Life Sciences is Pleased to Regain Full Compliance with Nasdaq, Continues to Execute on Clinical Development Strategy and Advance all Three Core Indications Forward
NEW YORK, NY, September 2, 2026 - Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (“CNS”) diseases with high unmet medical needs, today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires Nasdaq-listed companies to file all required periodic filings with the Securities and Exchange Commission (“SEC”).
On August 28, 2026, the Company filed its outstanding Form 10-Q filings for the second and third fiscal quarters of 2026 with the SEC. The Company is now in compliance with all Nasdaq listing standards, and its common stock will continue to trade on the Nasdaq Global Select Market under the ticker “AVXL.”
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded clinical stage biopharmaceutical company engaged in the development of novel therapeutics for the treatment of central nervous system (“CNS”) diseases with high unmet medical need. Further information is available at www.anavex.com.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include, but are not limited to, statements relating to the Company’s ability to continue trading on the Nasdaq Global Select Market. These statements are based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such forward-looking statements due to various factors, including, but not limited to, risks related to the Company’s ability to maintain compliance with the Nasdaq Listing Rules; and other risks and uncertainties set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025, filed with the Securities and Exchange Commission (“SEC”) on November 25, 2025, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2025, filed with the SEC on February 9, 2026, the Company’s Form 10-K/A for the fiscal year ended September 30, 2025, filed with the SEC on August 28, 2026, the Company’s Form 10-Q/A for the quarterly period ended December 31, 2025, filed with the SEC on August 28, 2026, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, filed with the SEC on August 28, 2026, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 28, 2026, and subsequent filings and furnishings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof except as required by law.
Investor Relations & Media Contact:
SCR Partners, LLC
Alex Arzeno
Tel: 203-550-3972
Email: alex@scr-ir.com
Tripp Sullivan
Tel: 615-942-7077
Email: tsullivan@scr-ir.com
Company Contact:
Sandra Boenisch
Principal Financial Officer
Anavex Life Sciences Corp.
Tel: 1-844-689-3939
Email: ir@anavexcorp.com